I am not so sure about the BS of the appraisal. In the end it was not JM who did it, it was an external company, and yet another company helping GNBT with IPO, so they must have looked at the appraisal as well, and considered it valid. Back then, when the appraisal came out both JM and we here were disappointed about the rather "conservative" evaluation, as it did not include anything related to the Covid vaccine. AE, with EvH at its helm, has a track record of doing R&D work for several decades (2 at least), they have patents on the II-key technology, the second stage clinical trial breast cancer medication (with 10 years of clinical data, as JM was not getting tired of pointing out, time and time again) and other developments in the pre clinical stages. All this is supposed to be worth something.
In regards to tax write offs, at least for me here in Germany, that would only be possible, if I could realize my losses, meaning sell my shares. As long as I still own these shares, they are considered virtual losses, and I cannot use them against other capital gains, which is a real dilemma.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links